Related references
Note: Only part of the references are listed.Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates
Thomas Jouve et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis
Aurelie Truffot et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2021)
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Nicolino Ruperto et al.
RHEUMATOLOGY (2021)
Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation
Johan Noble et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates
Melanie Daligault et al.
TRANSPLANTATION DIRECT (2021)
Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components
Carla Bastida et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis
Uri Arad et al.
JOURNAL OF RHEUMATOLOGY (2019)
Desensitization in the Era of Precision Medicine: Moving From the Bench to Bedside
Marlena V. Habal et al.
TRANSPLANTATION (2019)
A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease
Theo Willeman et al.
ANALYTICA CHIMICA ACTA (2019)
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab
Cesar Diaz-Torne et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in PatientsWith Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
Hisham Abdallah et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study
E. L. Kneepkens et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2017)
Immunogenicity of tocilizumab in patients with rheumatoid arthritis
Johanna Sigaux et al.
JOINT BONE SPINE (2017)
Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis
Miriam Manook et al.
LANCET (2017)
Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors
B. J. Orandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab
Maurizio Benucci et al.
BIOLOGICS-TARGETS & THERAPY (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
David Ternant et al.
CLINICAL PHARMACOKINETICS (2015)
A Phase I/II Trial of the Interleukin-6 Receptor Specific Humanized Monoclonal (Tocilizumab) plus Intravenous Immunoglobulin in Difficult to Desensitize Patients
Ashley A. Vo et al.
TRANSPLANTATION (2015)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Rituximab and intravenous immune globulin for desensitization during renal transplantation
Ashley A. Vo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
